DocuSign Beats and Still Falls. Buy or Walk Away?

Hey there, bargain hunter. Most investors are going to spend the next four days watching DocuSign’s revenue line. That’s the wrong game. Bank of America flagged on August 28 that annual recurring revenue guidance will command the real attention when DocuSign posts its fiscal second-quarter results after the close on September 3. The revenue number almost doesn’t matter. The ARR guide does.

Scoreboard

DocuSign reports after the close on September 3, 2026. Last quarter it delivered $1.09 in non-GAAP EPS, beating consensus rather than missing it. This time, consensus sits at $1.08 EPS on roughly $868 million in revenue. Management guided Q2 revenue to $865–$869 million, implying about 8% growth at the midpoint. The share price has done its own damage: DOCU is down about 15% over the past 52 weeks.

What Actually Happened

Bank of America believes its guidance for annual recurring revenue will get increased attention from investors. The logic is straightforward. DocuSign beat on Q1 fiscal 2027, with non-GAAP EPS of $1.09 topping estimates by about 9%, on revenue of $830.2 million that rose about 9% year over year. The better-than-expected results failed to impress the market, and the stock fell 7.2% in the days following that June 4 release. Beating the quarter and getting punished for it is a pattern the market has established. The forward ARR guide is where trust gets rebuilt or broken.

The Business, Plainly

DocuSign provides electronic signature solutions and an AI-powered intelligent agreement management platform covering the entire agreement lifecycle, from e-signature and contract lifecycle management to document generation. The old model was simple: sign here. The new model is more ambitious. IAM represented 12.6% of total ARR as of April 30, 2026, compared to 10.8% as of January 31, 2026. The company remains on track for IAM to represent approximately 18% of total ARR at the end of fiscal 2027, which would put IAM at well over $600 million in ARR. That trajectory is what BofA wants to see confirmed in the Q2 ARR guide.

The Numbers

• Q1 FY2027 revenue: $830.2 million, up about 9% year over year.
• Operating margin: 32%. Free cash flow margin: 35%. Record $318 million in share buybacks in Q1.
• Trailing twelve-month free cash flow: about $1.1 billion.
• Full-year FY2027 guidance: revenue of $3.490–$3.502 billion, non-GAAP operating margin of 30.5%–31.0%, ARR growth of 8.25%–8.75%.
• Dollar net retention improved to 102%.
• Share repurchase capacity expanded to $2.6 billion. As of the end of Q1, the company said it had $2.4 billion remaining under the authorization.

Is It Cheap?

Valuation multiples move around with the stock, so treat point estimates with caution. At around $64, DOCU has a market cap of about $12.6 billion. For a software company with roughly a $1.1 billion free cash flow run rate, that can still look inexpensive depending on what you assume for durability and reinvestment. Compare that to Adobe or Salesforce, where you routinely pay materially higher sales multiples for slower incremental ARR growth. DOCU trades like a melting ice cube. The cash flow says otherwise.

At around $64, DOCU is above the $59 level referenced earlier. The question is whether IAM proves that the underlying growth rate warrants any re-rating. That answer comes September 3.

Bull / Base / Bear

Bull: IAM ARR share accelerates beyond 13% in Q2, the full-year guide gets nudged higher, and the buyback machine shrinks the float faster than the stock price reflects. DocuSign repurchased $317.5 million of stock in Q1 alone, against a market cap that has compressed sharply.

Base: ARR guide comes in at the midpoint of the existing 8.25%–8.75% range. No upside surprise, but retention holds, margins stay above 30%, and the free cash flow profile keeps a floor under the stock.

Bear: IAM adoption stalls, the ARR guide disappoints, and the story that e-signature is ex-growth with no credible upsell reasserts itself. Competitive pressures in the maturing e-signature market remain a genuine risk.

Action Plan

This is a hold-into-earnings with a scaled-entry framework for the patient bargain hunter. Do not size a full position pre-report. The stock has shown it can gap down hard on a soft guide, even when the headline beat lands. Instead: take a starter position now, then add on a post-earnings pullback if the ARR guide is flat-to-positive and free cash flow guidance is intact. If IAM share climbs above 14% of ARR in the Q2 report, that is a signal the platform is additive, not cosmetic.

Cheap Investor Checklist

• ARR guide for FY2027: must hold 8.25%–8.75% range or better
• IAM as percentage of ARR: watch for above 13% in Q2
• Free cash flow margin: needs to stay at or above 30%
• Share buyback pace: $300 million-plus per quarter signals conviction
• Dollar net retention: improvement above 102% would be a positive signal
• Non-GAAP operating margin: floor is 30.5% per company guidance
• Revenue versus the $865–$869 million guided band
• Relative value check after earnings: compare sales and cash flow multiples versus Adobe and Salesforce

Bottom Line

If DocuSign’s ARR guide holds or ticks up on September 3, you are buying a roughly $1.1 billion free cash flow business with an aggressive buyback program and a platform that is still proving itself. If the ARR guide disappoints and IAM momentum stalls, the stock has room to fall further regardless of what the quarter shows. The market stopped calling this a growth stock. That is exactly when the numbers-first bargain hunter starts doing the math.